| P/E (FY) | — | Sales (TTM) | $45.1M |
| Earnings (TTM) | -$43.6M | ROE | −61.52% |
| Net Margin | −133.45% | ROIC | — |
| Debt / Equity | — | TD / EBITDA | — |
| EPS Growth 3Y | — | Sales Growth 3Y | 10.93% |
| Market Cap | $185.0M | Trading Days | 1838 |
| 52W High | 9.62 |
| 52W Low | 3.53 |
| % Off High | −25.47% |
| YTD | 72.36% | 1Y | 40.59% |
| 3Y | −57.90% | 5Y | −97.66% |
| Since incept. (ann.) | −44.36% |
Operating 100%
| Ann. Volatility (1Y) | 70.76% | Ann. Volatility (3Y) | 77.49% |
| Sharpe (1Y) | 0.84 | Sharpe (3Y) | 0.00 |
| Max Drawdown (1Y) | −58.54% | Max Drawdown (3Y) | −80.77% |
| Beta (3Y, vs SPY) | 1.99 |
| Ticker | Name | Mkt cap | P/E |
|---|---|---|---|
| LENZ | LENZ Therapeutics, Inc. | $184.4M | — |
| VYGR | Voyager Therapeutics, Inc. | $183.7M | — |
| ACOG | Alpha Cognition Inc. | $183.1M | — |
| PLX | Protalix BioTherapeutics, Inc. | $187.7M | — |
| CRIS | CURIS INC | $188.3M | — |
| ALGS | Aligos Therapeutics, Inc. | $181.1M | — |
| BCDA | BioCardia, Inc. | $180.0M | — |
| IVVD | Invivyd, Inc. | $174.8M | — |
| ALEC | Alector, Inc. | $168.8M | — |
| BCAB | BioAtla, Inc. | $207.7M | — |
| ABOS | Acumen Pharmaceuticals, Inc. | $164.7M |
| TNYA | Tenaya Therapeutics, Inc. | $164.1M | — |
